Skip to Content

Generic Lidex Availability

Lidex is a brand name of fluocinonide topical, approved by the FDA in the following formulation(s):

LIDEX (fluocinonide - cream;topical)

  • Manufacturer: CNTY LINE PHARMS
    Approved Prior to Jan 1, 1982
    Strength(s): 0.05%

LIDEX (fluocinonide - gel;topical)

  • Manufacturer: CNTY LINE PHARMS
    Approved Prior to Jan 1, 1982
    Strength(s): 0.05%

LIDEX (fluocinonide - ointment;topical)

  • Manufacturer: CNTY LINE PHARMS
    Approved Prior to Jan 1, 1982
    Strength(s): 0.05% [AB]

LIDEX (fluocinonide - solution;topical)

  • Manufacturer: CNTY LINE PHARMS
    Approval date: April 6, 1984
    Strength(s): 0.05% [AT]

Has a generic version of Lidex been approved?

Yes. The following products are equivalent to Lidex:

fluocinonide solution;topical

  • Manufacturer: FOUGERA
    Approval date: February 27, 1995
    Strength(s): 0.05% [AT]
  • Manufacturer: G AND W LABS INC
    Approval date: December 2, 1988
    Strength(s): 0.05% [AT]
  • Manufacturer: TEVA
    Approval date: February 7, 1989
    Strength(s): 0.05% [AT]

Note: No generic formulation of the following products are available.

  • fluocinonide - cream;topical
  • fluocinonide - gel;topical
  • fluocinonide - ointment;topical

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Lidex. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.


Drug PatentA drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation.
Drug ExclusivityExclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant.
ABProducts meeting necessary bioequivalence requirements. Multisource drug products listed under the same heading (i.e., identical active ingredients(s), dosage form, and route(s) of administration) and having the same strength (see Therapeutic Equivalence-Related Terms, Pharmaceutical Equivalents) generally will be coded AB if a study is submitted demonstrating bioequivalence. In certain instances, a number is added to the end of the AB code to make a three character code (i.e., AB1, AB2, AB3, etc.). Three-character codes are assigned only in situations when more than one reference listed drug of the same strength has been designated under the same heading. Two or more reference listed drugs are generally selected only when there are at least two potential reference drug products which are not bioequivalent to each other. If a study is submitted that demonstrates bioequivalence to a specific listed drug product, the generic product will be given the same three-character code as the reference listed drug it was compared against.
ATTopical products. There are a variety of topical dosage forms available for dermatologic, ophthalmic, otic, rectal, and vaginal administration, including creams, gels, lotions, oils, ointments, pastes, solutions, sprays and suppositories. Even though different topical dosage forms may contain the same active ingredient and potency, these dosage forms are not considered pharmaceutically equivalent. Therefore, they are not considered therapeutically equivalent. All solutions and DESI drug products containing the same active ingredient in the same topical dosage form for which a waiver of in vivo bioequivalence has been granted and for which chemistry and manufacturing processes are adequate to demonstrate bioequivalence, are considered therapeutically equivalent and coded AT. Pharmaceutically equivalent topical products that raise questions of bioequivalence, including all post-1962 non-solution topical drug products, are coded AB when supported by adequate bioequivalence data, and BT in the absence of such data.